Is Reducing Heart Failure Hospitalization Associated With Reducing Mortality in Heart Failure Trials?

Autores da FMUP

• João Pedro Melo Marques Pinho Ferreira

  Autor

Participantes de fora da FMUP

• Marques P.
• Sharma A.

Unidades de investigação

• Cirurgia e Fisiologia

• Laboratório Associado RISE- Rede de Investigação em Saúde

  

  Investigador

  Fernando Carlos De Landér Schmitt

Abstract

[No abstract available]

Keywords

• Heart Failure; Hospitalization; Humans; candesartan; dapagliflozin; digoxin; dronedarone; empagliflozin; enalapril; eplerenone; irbesartan; ivabradine; levosimendan; omecamtiv mecarbil; placebo; rivaroxaban; rosuvastatin; sacubitril plus valsartan; spironolactone; valsartan; vericiguat; ablation therapy; all cause mortality; atrial fibrillation; cardiovascular mortality; causal attribution; clinical effectiveness; disease association; disease exacerbation; drug efficacy; Editorial; heart failure; hospitalization; human; incidence; morbidity; prevalence; prognosis; treatment outcome; treatment planning; heart failure